section name header

Indications

High Alert

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: altered visual acuity, ocular disorders, visual disturbances, visual field defects, earache, hearing loss.

Resp: asthma, laryngeal edema.

CV: CARDIAC FAILURE, MI, STROKE, arrhythmias, chest discomfort, edema, hypertension, hypotension, peripheral edema, phlebitis.

GI: GI BLEEDING, abdominal distention, abdominal pain, anorexia, constipation, diarrhea, dry mouth, dyspepsia, hepatosplenomegaly, mucositis, nausea, ulcer, vomiting.

GU: renal insufficiency, acute renal failure, dysuria, enlarged prostate, renal tubular necrosis, urinary frequency.

Derm: alopecia, cellulitis, dry skin, facial edema, flushing, sweating, pallor, pruritus, rash, skin changes.

F and E: acidosis, fluid imbalance.

Hemat: disseminated intravascular coagulation, hemorrhage, leukocytosis.

Metab: weight gain, weight loss.

MS: bone inflammation, bone pain, flank pain, myalgia.

Neuro: paresthesias, SEIZURES, anxiety, confusion, depression, dizziness, fatigue, headache, insomnia, malaise, pseudotumor cerebri, weakness, agitation, cerebral hemorrhage, hallucinations, intracranial hypertension.
Misc: fever, infections, pain, hypothermia, retinoic acid–acute promyelocytic leukemia syndrome, shivering.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Availability

(Generic available)

Route/Dosage

see Calculator

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: retinoids

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Crosses the placenta; remainder of distribution unknown.

Protein Binding: >95%.

Metabolism/Excretion: Metabolized by the liver; metabolites are renally excreted.

Half-life: 0.5–2 hr.

Time/Action Profile

(complete remission)

ROUTEONSETPEAKDURATION
POunknown40–50 daysunknown

Patient/Family Teaching

Pronunciation

TRET-i-noyn